Featured CPE Activity

How Would You Treat This Patient?

 

Add a heading 150 100 px 200 150 px 300 150 px 500 150 px


Faculty Spotlight

“Response depth does not predict overall survival in Waldenstrom macroglobulinemia. This is not intuitive because response depth always predicts survival in myeloma and amyloidosis. . . Therefore, if you treat a patient and they failed to achieve a PR, that doesn’t mean they failed treatment; that doesn’t mean that you need to initiate second-line therapy. It depends on why you treated them in the first place.” - Morie Gertz, MACP

Morie Gertz, MD, is the Roland Seidler Jr. Professor in the Department of Medicine and Chair of General Internal Medicine at the Mayo Clinic in Rochester, Minnesota. He specializes in the treatment of patients with Waldenstrom macroglobulinemia, amyloidosis, and multiple myeloma, including those undergoing stem cell transplantation. Dr. Gertz serves as a member of the American Board of Internal Medicine’s Hematology Approval Committee, and he has authored or coauthored more than 700 manuscripts focusing on research for hematological malignancies.


Additional Resources

For additional information and unique perspectives on multiple myeloma treatment and patient care, check out the expert interviews listed below.

Add a heading 150 100 px 200 150 px 300 150 px 500 150 px

Copyright © 2022 i3 Health. All rights reserved.